7/8/2009

MedImmune secured the rights to use Catalyst Biosciences' technology in conducting studies on autoimmune and inflammatory conditions. The deal, worth as much as $195 million, allows Catalyst to receive upfront payments, milestone fees and royalties from MedImmune.

Related Summaries